The kratom debate just got sharper after two Ole Miss student deaths drew national attention to products found near the scene. Industry advocates are pushing hard to separate the natural leaf from synthetic drugs that they say are being mislabeled, while investigators continue waiting on toxicology results and sorting out exactly what was recovered.
What started as a grim campus tragedy quickly turned into a fight over language, labeling, and public safety. Court documents said Aidan Hamilton, 18, and Robert Strang, 20, were found dead on Sept. 21 at separate locations, and early reports linked packaged kratom or synthetic kratom to both scenes. Later, investigators narrowed that description, saying only that packaging tied to kratom-related products had been found.
That change matters to kratom supporters, who say the distinction between a leaf product and a lab-made opioid is huge. Mac Haddow of the American Kratom Association argued that the first description risked lumping together two very different things, and that natural kratom should not be blamed for harms tied to chemically altered substances.
According to court records, the items found near both students carried the Modus name. The affidavit also described tablets labeled Smax Pseudo-DHM and listed pseudoindoxyl and MGM-15(DHM) among the ingredients found near Hamilton, details that only deepened concerns about synthetic compounds entering the market under kratom-adjacent branding.
Haddow said the association pressed police for clarification after the original reports spread, and then held a news conference in Oxford to challenge the wording. His argument was simple: if the products were chemically manipulated opioids, they should be treated that way, not as kratom. He said that kind of mix-up feeds fear about a plant that consumers see as a different category entirely.
The Mississippi Kratom Consumer Protection Act adds another layer to the story. The law does not ban kratom, but it sets rules for who can sell it, how it must be labeled, and which products are allowed, while also trying to block adulterated or overly potent items from slipping through. Haddow questioned why those guardrails were not being enforced if the products near the students were in fact synthetic.
Supporters of kratom often point to its long history in Southeast Asia, where the leaves have been used for generations. They also say no published reports clearly tie traditional leaf use there to deaths, even though researchers have documented some adverse effects connected to long-term use. That distinction between traditional use and concentrated products is at the center of the current dispute.
Haddow also argued that the United States saw a wave of interest in kratom after the Vietnam War, though researchers have said that origin story is not firmly established in the literature. What is better documented is the long tug-of-war between kratom and federal regulators. The FDA issued an import alert in 2012, and the DEA later floated a Schedule I move in 2016 before backing off after public comment.
More recently, federal agencies have focused on concentrated or chemically modified products, including ones with high levels of 7-hydroxymitragynine, or 7-OH. Haddow said those products are not the same as natural kratom at all, describing them as altered compounds that were intentionally engineered to hit consumers like an opioid. He argued that the real problem is not the leaf but the people who tamper with it.
The industry’s broader message is that enforcement should target those synthetic products, not the natural plant. Haddow compared the issue to caffeine in coffee, saying the source product should not be blamed if someone extracts and concentrates a substance into something dangerous. In his view, the same logic should apply to kratom, where the raw leaf and the modified version are worlds apart.
That argument also ties into the group’s push for tighter rules instead of blanket bans. Age limits, testing, and clearer labels are the safeguards Haddow keeps returning to, along with a hard line against products he says are really opioids wearing kratom’s name. He said consumers deserve the truth about what is on the shelf, especially when dangerous compounds are being sold in a way that can confuse buyers.
The FDA, meanwhile, still says kratom has not been approved for any medical use and warns about dependence, contamination, and adverse events. Research is still ongoing, including studies looking at purified mitragynine and whether it could one day play a role in treating opioid use disorder. For now, the fight over these products is unfolding in public, with officials, advocates, and regulators all trying to define what should and should not be called kratom.
